Tezepelumab, a fully human monoclonal IgG2λ antibody currently indicated for the treatment of severe asthma, specifically binds human TSLP at the level of its ligation site for TSLPR, thereby impeding the TSLP-TSLPR interaction [16]. The gene discussed is CRLF2; the disease is asthma.